Nalaganje...
Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
The discovery of JAK2617F mutation paved the way for the development of small molecule inhibitors of JAK1/2 resulting in first approved JAK1/2 inhibitor, ruxolitinib, for the treatment of patients with myelofibrosis (MF). Although JAK1/2 inhibitor therapy is effective in decreasing the burden of sym...
Shranjeno v:
| izdano v: | Blood |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2012
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5800543/ https://ncbi.nlm.nih.gov/pubmed/22700718 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-05-399048 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|